Sana's 14-Month UP421 Data Show Durable Islet Survival Without Immunosuppression
SANA sits 47% above its 52-week low of $2.61.
Summary
Sana's September 2026 corporate presentation shows 14-month durability for its hypoimmune islet cell therapy in type 1 diabetes, with continued insulin production and no adverse events, and sets 2026/2027 milestones for its SC451 and in vivo CAR T programs.
Key Events · Product Development and Regulatory · SANA
-
14-Month UP421 Data Show Durable Function
HIP islet cells continue to produce C-peptide through 14 months in a type 1 diabetes patient with no therapy-related adverse events, extending prior 12-month data.
-
SC451 IND Filing Targeted for 2026
Company reaffirms goal to file IND and begin Phase 1/2 trial for SC451 this year; GMP master cell bank completed and clinical sites selected.
-
In Vivo CAR T Milestones Set
SG293 in non-Hodgkin lymphoma could share first-in-human data in 1H 2027; SG227 in multiple myeloma expected to begin clinical study as early as 2027.
-
Mayo Clinic Collaboration
Collaboration brings capital and support for building a broad patient delivery model for SC451.
Analysis · SANA · Life Sciences
The updated corporate presentation provides the longest follow-up yet for Sana's hypoimmune islet cell therapy in type 1 diabetes. At 14 months, the transplanted cells continue to produce C-peptide with no therapy-related adverse events, supporting the core thesis that hypoimmune edits can eliminate the need for lifelong immunosuppression. The company also reaffirms its 2026 goal to file an IND for SC451 and start a Phase 1/2 trial, and discloses first-in-human data timing for its in vivo CAR T programs (SG293 in 1H 2027, SG227 as early as 2027). This matters because Sana is a pre-revenue biotech with a going concern warning and only $160.5M in cash as of Q2 2026 — positive clinical validation is critical to its ability to raise capital and extend runway.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SANA was trading at $3.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.61 to $6.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.